DRUG_GROUP	Trade_Name	Active_Ingredient	MARKETING_DATE	BBW_DATE	POPULAR_YEAR	SUMMARY	SOURCE	BBW_TEXT	label
ROBUST	aciphex	NA	1999-08-19	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	actonel	NA	1998-03-27	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	afinitor	NA	2009-03-31	NA	[2013]	NA	NA	NA	0
ROBUST	aggrenox	NA	1999-12-19	NA	[2006, 2007, 2009, 2010]	NA	NA	NA	0
ROBUST	aldara	NA	2011-06-24	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009]	NA	NA	NA	0
ROBUST	alimta	NA	2004-02-13	NA	[2011, 2012, 2013]	NA	NA	NA	0
ROBUST	allegra-d 24 hour	NA	2004-10-19	NA	[2007, 2008, 2009]	NA	NA	NA	0
ROBUST	alphagan p	NA	2001-07-10	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009]	NA	NA	NA	0
ROBUST	amaryl	NA	2009-06-18	NA	[2003, 2004, 2005]	NA	NA	NA	0
ROBUST	ambien	NA	1993-04-01	NA	[2003, 2004, 2005, 2006, 2007]	NA	NA	NA	0
ROBUST	ambien cr	NA	2005-10-07	NA	[2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	amitiza	NA	2006-01-31	NA	[2008, 2009, 2010]	NA	NA	NA	0
ROBUST	aricept	NA	1996-11-25	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	arimidex	NA	1996-01-16	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	asacol	NA	1992-04-01	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	asmanex	NA	2005-03-30	NA	[2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	astelin	NA	1996-11-15	NA	[2005, 2006, 2007, 2008, 2009]	NA	NA	NA	0
ROBUST	avodart	NA	2002-12-10	NA	[2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	avonex	NA	1996-05-17	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	bactroban	NA	1996-04-10	NA	[2003]	NA	NA	NA	0
ROBUST	benzaclin	NA	2009-08-27	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009]	NA	NA	NA	0
ROBUST	betaseron	NA	2009-07-09	NA	[2003, 2004, 2005, 2006, 2007, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	biaxin	NA	1991-10-31	NA	[2003, 2004]	NA	NA	NA	0
ROBUST	boniva	NA	2002-07-15	NA	[2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	byetta	NA	2005-04-28	NA	[2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	bystolic	NA	2008-01-22	NA	[2010]	NA	NA	NA	0
ROBUST	caduet	NA	2004-01-30	NA	[2005, 2006, 2007, 2009, 2010]	NA	NA	NA	0
ROBUST	casodex	NA	1995-10-16	NA	[2003, 2004, 2005, 2006, 2007, 2008]	NA	NA	NA	0
ROBUST	cialis	NA	2003-11-26	NA	[2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	clarinex	NA	2001-12-21	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009]	NA	NA	NA	0
ROBUST	clobex	NA	2003-08-01	NA	[2010]	NA	NA	NA	0
ROBUST	combivent respimat	NA	2012-08-24	NA	[2013]	NA	NA	NA	0
ROBUST	copaxone	NA	2008-04-28	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	coreg	NA	1997-06-03	NA	[2003, 2004, 2005, 2006, 2007]	NA	NA	NA	0
ROBUST	cosopt	NA	1998-04-07	NA	[2003, 2004, 2005, 2006, 2007, 2008]	NA	NA	NA	0
ROBUST	creon	NA	2009-09-29	NA	[2010]	NA	NA	NA	0
ROBUST	crestor	NA	2003-08-18	NA	[2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	ddavp	NA	1978-02-21	NA	[2003, 2004, 2005]	NA	NA	NA	0
ROBUST	detrol la	NA	2000-02-22	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	dexilant	NA	2010-04-12	NA	[2012, 2013]	NA	NA	NA	0
ROBUST	differin	NA	1996-05-31	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	diflucan	NA	1990-01-29	NA	[2003, 2004]	NA	NA	NA	0
ROBUST	doryx	NA	2011-09-21	NA	[2008, 2009, 2010]	NA	NA	NA	0
ROBUST	dovonex	NA	1996-10-01	NA	[2003, 2004, 2006, 2007]	NA	NA	NA	0
ROBUST	duoneb	NA	2011-02-15	NA	[2004, 2005, 2006]	NA	NA	NA	0
ROBUST	elmiron	NA	1996-09-26	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	enablex	NA	2004-12-22	NA	[2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	epipen	NA	1987-12-22	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	famvir	NA	1994-06-29	NA	[2003, 2004, 2005, 2006, 2007]	NA	NA	NA	0
ROBUST	femara	NA	1997-07-31	NA	[2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	flomax	NA	1997-09-12	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	flonase	NA	1994-11-08	NA	[2003, 2004, 2005, 2006]	NA	NA	NA	0
ROBUST	flovent	NA	2005-07-13	NA	[2003, 2004, 2005]	NA	NA	NA	0
ROBUST	fosamax	NA	1995-09-29	NA	[2003, 2004, 2005, 2006, 2007, 2008]	NA	NA	NA	0
ROBUST	fosamax plus d	NA	2005-04-07	NA	[2006, 2007, 2008]	NA	NA	NA	0
ROBUST	fuzeon	NA	2012-04-10	NA	[2004, 2005, 2006, 2007]	NA	NA	NA	0
ROBUST	gilenya	NA	2010-09-21	NA	[2012, 2013]	NA	NA	NA	0
ROBUST	gleevec	NA	2001-05-15	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	glucotrol xl	NA	1994-08-01	NA	[2003]	NA	NA	NA	0
ROBUST	gonal-f	NA	2004-03-25	NA	[2003]	NA	NA	NA	0
ROBUST	humalog	NA	1996-07-24	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	humulin 70/30	NA	2013-06-12	NA	[2003, 2004, 2005, 2006, 2008]	NA	NA	NA	0
ROBUST	intuniv	NA	2009-09-02	NA	[2010]	NA	NA	NA	0
ROBUST	isentress	NA	2007-10-12	NA	[2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	januvia	NA	2006-10-16	NA	[2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	kaletra	NA	2006-04-11	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	keppra	NA	2000-04-24	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	klor-con	NA	1986-04-17	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009]	NA	NA	NA	0
ROBUST	lantus	NA	2002-06-04	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	lantus solostar	NA	2009-09-23	NA	[2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	lescol	NA	1993-12-30	NA	[2003]	NA	NA	NA	0
ROBUST	levemir	NA	2006-03-27	NA	[2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	levitra	NA	2003-04-23	NA	[2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	lialda	NA	2007-01-16	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	lidoderm	NA	1999-03-20	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	lipitor	NA	1996-12-17	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012]	NA	NA	NA	0
ROBUST	lovaza	NA	2008-10-21	NA	[2007, 2008, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	lucentis	NA	2006-06-30	NA	[2011, 2012, 2013]	NA	NA	NA	0
ROBUST	lumigan	NA	2001-03-22	NA	[2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	lunesta	NA	2005-04-04	NA	[2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	lyrica	NA	2004-12-30	NA	[2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	macrobid	NA	2011-05-31	NA	[2003]	NA	NA	NA	0
ROBUST	marinol	NA	2010-07-13	NA	[2007]	NA	NA	NA	0
ROBUST	maxalt	NA	1998-06-29	NA	[2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	mirapex	NA	2003-09-04	NA	[2004, 2005, 2006, 2007, 2008, 2009]	NA	NA	NA	0
ROBUST	namenda	NA	2003-10-16	NA	[2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	nasacort aq	NA	1996-05-20	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	nasonex	NA	1997-10-01	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	neulasta	NA	2002-04-01	NA	[2011, 2012, 2013]	NA	NA	NA	0
ROBUST	neupogen	NA	1994-06-08	NA	[2003, 2004, 2005, 2006, 2007, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	neurontin	NA	1993-12-30	NA	[2003, 2004, 2005]	NA	NA	NA	0
ROBUST	nexium	NA	2001-03-19	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	niaspan	NA	1997-07-28	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	norvasc	NA	1992-07-31	NA	[2003, 2004, 2005, 2006, 2007]	NA	NA	NA	0
ROBUST	novolog	NA	2001-08-27	NA	[2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	novolog mix 70/30	NA	2002-09-11	NA	[2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	nuvigil	NA	2009-05-26	NA	[2010]	NA	NA	NA	0
ROBUST	oracea	NA	2006-09-29	NA	[2010]	NA	NA	NA	0
ROBUST	orencia	NA	2009-01-01	NA	[2012, 2013]	NA	NA	NA	0
ROBUST	pataday	NA	2007-02-15	NA	[2010]	NA	NA	NA	0
ROBUST	patanol	NA	1997-02-17	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	penlac	NA	1999-12-17	NA	[2003]	NA	NA	NA	0
ROBUST	pentasa	NA	1993-05-10	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	prandin	NA	2000-01-03	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	pravachol	NA	2009-06-01	NA	[2003, 2004, 2005, 2006]	NA	NA	NA	0
ROBUST	prevacid	NA	1995-05-10	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	prevpac	NA	1997-12-02	NA	[2003]	NA	NA	NA	0
ROBUST	prezista	NA	2008-03-08	NA	[2009, 2010, 2012, 2013]	NA	NA	NA	0
ROBUST	prilosec	NA	1990-10-01	NA	[2003, 2004, 2005, 2006, 2007]	NA	NA	NA	0
ROBUST	propecia	NA	1997-12-19	NA	[2008, 2009, 2010]	NA	NA	NA	0
ROBUST	proscar	NA	1992-06-19	NA	[2003, 2004, 2005, 2006]	NA	NA	NA	0
ROBUST	protonix	NA	2000-05-01	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	proventil hfa	NA	2001-10-01	NA	[2008, 2009, 2010]	NA	NA	NA	0
ROBUST	provigil	NA	1998-12-24	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011]	NA	NA	NA	0
ROBUST	pulmicort respules	NA	2000-09-08	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	pulmozyme	NA	1993-12-30	NA	[2005, 2006, 2007]	NA	NA	NA	0
ROBUST	qvar	NA	2000-09-15	NA	[2010]	NA	NA	NA	0
ROBUST	ranexa	NA	2006-01-27	NA	[2010]	NA	NA	NA	0
ROBUST	rebif	NA	2002-03-07	NA	[2004, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	relpax	NA	2002-12-26	NA	[2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	renagel	NA	2008-06-06	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	renvela	NA	2009-08-12	NA	[2010, 2012, 2013]	NA	NA	NA	0
ROBUST	requip	NA	1997-10-01	NA	[2006, 2007, 2008]	NA	NA	NA	0
ROBUST	restasis	NA	2003-04-01	NA	[2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	reyataz	NA	2003-06-24	NA	[2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	rhinocort aqua	NA	2001-04-02	NA	[2003, 2004, 2005, 2006, 2007, 2008]	NA	NA	NA	0
ROBUST	sensipar	NA	2004-04-04	NA	[2006, 2007, 2008, 2009, 2010, 2013]	NA	NA	NA	0
ROBUST	singulair	NA	1998-02-20	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012]	NA	NA	NA	0
ROBUST	skelaxin	NA	1962-08-13	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	solodyn	NA	2009-07-23	NA	[2007, 2008, 2009, 2010, 2011]	NA	NA	NA	0
ROBUST	spiriva	NA	2004-07-14	NA	[2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	stelara	NA	2009-09-25	NA	[2013]	NA	NA	NA	0
ROBUST	suboxone	NA	2007-01-16	NA	[2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	sustiva	NA	1998-09-17	NA	[2003, 2004, 2005, 2006, 2007, 2008]	NA	NA	NA	0
ROBUST	synagis	NA	1998-06-19	NA	[2011, 2012, 2013]	NA	NA	NA	0
ROBUST	taclonex	NA	2008-06-01	NA	[2008, 2009]	NA	NA	NA	0
ROBUST	tamiflu	NA	1999-10-27	NA	[2005, 2008, 2009, 2013]	NA	NA	NA	0
ROBUST	tarceva	NA	2005-04-30	NA	[2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	tecfidera	NA	2013-03-27	NA	[2013]	NA	NA	NA	0
ROBUST	temodar	NA	1999-08-11	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	tiazac	NA	2010-12-25	NA	[2003]	NA	NA	NA	0
ROBUST	tobradex	NA	1988-08-18	NA	[2003, 2004, 2005, 2006, 2007, 2008]	NA	NA	NA	0
ROBUST	topamax	NA	1997-01-01	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	travatan z	NA	2006-10-20	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	tricor	NA	2004-11-05	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012]	NA	NA	NA	0
ROBUST	trileptal	NA	2000-01-30	NA	[2003, 2004, 2005, 2006, 2007, 2008]	NA	NA	NA	0
ROBUST	trilipix	NA	2008-12-15	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	ultram er	NA	2005-09-08	NA	[2007, 2008, 2009]	NA	NA	NA	0
ROBUST	uroxatral	NA	2004-06-22	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	valtrex	NA	1995-08-01	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	velcade	NA	2003-05-13	NA	[2011]	NA	NA	NA	0
ROBUST	veramyst	NA	2007-05-15	NA	[2008, 2009, 2010]	NA	NA	NA	0
ROBUST	vesicare	NA	2005-01-05	NA	[2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	viagra	NA	1998-03-27	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	vigamox	NA	2003-05-07	NA	[2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	viracept	NA	1997-03-14	NA	[2003]	NA	NA	NA	0
ROBUST	vytorin	NA	2004-07-23	NA	[2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	welchol	NA	2000-09-01	NA	[2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	xalatan	NA	1995-03-20	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	xgeva	NA	2010-11-18	NA	[2013]	NA	NA	NA	0
ROBUST	xopenex	NA	1999-04-01	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	NA	NA	0
ROBUST	xopenex hfa	NA	2005-12-01	NA	[2008, 2009]	NA	NA	NA	0
ROBUST	xyzal	NA	2007-08-09	NA	[2009, 2010]	NA	NA	NA	0
ROBUST	zegerid	NA	2004-06-15	NA	[2009]	NA	NA	NA	0
ROBUST	zetia	NA	2002-10-25	NA	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	NA	NA	0
ROBUST	zithromax	NA	1994-09-28	NA	[2003, 2004, 2005]	NA	NA	NA	0
ROBUST	zocor	NA	1991-12-23	NA	[2003, 2004, 2005, 2006]	NA	NA	NA	0
ROBUST	zofran	NA	1991-02-04	NA	[2003, 2004, 2005, 2006]	NA	NA	NA	0
ROBUST	zometa	NA	2001-08-20	NA	[2011]	NA	NA	NA	0
ROBUST	zomig	NA	1998-01-10	NA	[2003, 2004, 2005, 2006, 2008]	NA	NA	NA	0
ROBUST	zonegran	NA	2000-03-27	NA	[2004, 2005]	NA	NA	NA	0
ROBUST	zytiga	NA	2011-04-28	NA	[2013]	NA	NA	NA	0
ROBUST	zyvox	NA	2000-04-18	NA	[2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012]	NA	NA	NA	0
BBW	abilify	aripiprazole	2002-11-15	2005-04-11	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	Increased Mortality in Patients with Dementia-Related Psychosis	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm151088.htm	Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; most deaths appeared to be either cardiovascular (CV) (eg, heart failure [HF], sudden death) or infectious (eg, pneumonia) in nature. Not approved for treatment of patients with dementia-related psychosis. Antidepressants increased risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Monitor and observe closely for clinical worsening, suicidality, or unusual changes in behavior in patients who are started on antidepressant therapy. Not approved for use in pediatric patients with depression.	1
BBW	accupril	NA	1991-11-19	2012-03-01	[2003, 2004]	NA	http://newyork.legalexaminer.com/fda-prescription-drugs/physicians-alert-the-public-to-potentially-lifethreatening-ace-inhibitor-side-effects/	D/C if pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	actiq	NA	1998-11-04	2007-02-01	[2003, 2004, 2005, 2006, 2007, 2008]	NA	http://www.defectivedrug.com/blackbox/actiq/	Fatal respiratory depression may occur. Contraindicated in the management of acute or postoperative pain (eg, headache/migraine) and in opioid-nontolerant patients. Death reported upon accidental ingestion in children; keep out of reach of children. Concomitant use with CYP3A4 inhibitors may increase plasma levels, and may cause fatal respiratory depression. Do not convert patients on a mcg-per-mcg basis from any other fentanyl products to Actiq. Do not substitute for any other fentanyl products; may result in fatal overdose. Contains fentanyl with abuse liability similar to other opioid analgesics. Available only through a restricted program called Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation Mitigation Strategy (REMS) Access program due to risk of misuse, abuse, addiction, and overdose. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program.	1
BBW	actoplus met	NA	2005-08-29	2007-08-01	[2007, 2008, 2009, 2010]	NA	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124178.htm	Thiazolidinediones, including pioglitazone, cause or exacerbate congestive heart failure (CHF) in some patients. After initiation and dose increases, monitor carefully for signs and symptoms of heart failure (HF); manage accordingly and consider discontinuation or dose reduction if HF develops. Not recommended with symptomatic HF. Contraindicated with established NYHA Class III or IV HF. Lactic acidosis may occur due to metformin accumulation; risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic/renal impairment, and acute CHF. If acidosis is suspected, d/c therapy and hospitalize patient immediately.	1
BBW	actos	NA	1999-07-15	2007-01-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012]	congestive heart failure	http://www.drugwatch.com/actos/black-box-warning.php	Thiazolidinediones cause or exacerbate congestive heart failure (CHF) in some patients. After initiation and dose increases, monitor carefully for signs and symptoms of heart failure (HF) and manage accordingly; consider discontinuation or dose reduction. Not recommended in patients with symptomatic HF. Contraindicated with established NYHA Class III or IV HF.	1
BBW	adderall xr	NA	2001-10-11	2006-08-22	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	sudden death in patients with heart problems.	http://www.webmd.com/add-adhd/news/20060822/heart-alert-adhd-drugs	High potential for abuse; prolonged use may lead to drug dependence. Misuse may cause sudden death and serious cardiovascular (CV) adverse reactions.	1
BBW	advair diskus	NA	2001-06-21	2006-06-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	http://www.lawyersandsettlements.com/articles/asthma/asthma-fda-black-box-warnings-10693.html#.VQkZQUvWqL4	long-acting beta-2 adrenergic agonists (LABA) incr. risk of asthma-related death; data from large placebo-controlled US study showed incr. in asthma-related deaths in pts receiving salmeterol plus usual asthma tx, results considered LABA class effect; inadequate data to determine if concurrent inhaled corticosteroids or other long-term asthma control tx mitigates incr. risk of asthma-related death from LABA; LABA use may incr. risk of asthma-related hospitalization in pediatric and adolescent pts; use only for asthma pts not controlled on long-term asthma control tx, such as inhaled corticosteroid, or whose dz severity requires tx w/ both corticosteroid and LABA; once asthma control is achieved and maintained, assess pt at regular intervals and step down tx, such as D/C corticosteroid/LABA combo, if possible w/o loss of asthma control; maintain pt on long-term asthma control tx such as inhaled corticosteroid; do not use corticosteroid/LABA combo if asthma adequately controlled on low-or medium-dose inhaled corticosteroids	1
BBW	altace	ramipril	1991-01-28	2012-04-01	[2003, 2004, 2005, 2006, 2007, 2008]	FETAL TOXICITY	http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm233254.htm	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	amnesteem	isotretinoin	2002-11-11	2007-03-01	[2003, 2004, 2005]	must not be used by female patients who are or may become pregnant.	http://isotretinoinsideeffects.com, http://www.fda.gov/downloads/iceci/enforcementactions/enforcementstory/enforcementstoryarchive/ucm090289.pdf	Not for use by females who are or may become pregnant. Severe birth defects, including death, have been documented. Increased risk of spontaneous abortion and premature births reported. D/C immediately if pregnancy occurs during treatment and refer to an obstetrician-gynecologist experienced in reproductive toxicity for evaluation and counseling. Approved only under special restricted distribution program called iPLEDGEŠÜ¢. Prescribers, patients, pharmacies, and distributors must be registered and activated with the program.	1
BBW	androgel	NA	2003-05-15	2009-05-07	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	The FDA today warned about the risks that testosterone gel products can pose to children inadvertently exposed to those products by adults	http://www.webmd.com/men/news/20090507/testosterone-gels-risky-to-children	Virilization reported in children secondarily exposed to testosterone gel. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel. Advise patients to strictly adhere to recommended instructions for use.	1
BBW	aranesp	NA	2006-06-07	2007-03-09	[2005, 2006, 2011, 2012, 2013]	NA	http://www.medpagetoday.com/ProductAlert/Prescriptions/5231	Increased risk of death, myocardial infarction (MI), stroke, venous thromboembolism (VTE), thrombosis of vascular access, and tumor progression or recurrence. Use the lowest dose sufficient to reduce/avoid the need for RBC transfusions. Chronic Kidney Disease (CKD): Greater risks for death, serious adverse cardiovascular (CV) reactions, and stroke when administered to target Hgb level of >11g/dL. Cancer: Shortened overall survival and/or increased risk of tumor progression or recurrence in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. Must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense drug to patients. Use only for anemia from myelosuppressive chemotherapy. Not indicated for patients receiving myelosuppressive chemotherapy when anticipated outcome is cure. D/C following completion of chemotherapy course.	1
BBW	arava	NA	1998-09-10	2010-07-13	[2003, 2004, 2005]	New boxed warning for severe liver injury with arthritis drug Arava (leflunomide)	http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm218679.htm	Pregnancy must be excluded before start of treatment. Avoid pregnancy during treatment or before completion of drug elimination procedure after treatment. Severe liver injury, including fatal liver failure, reported; not for use with preexisting acute or chronic liver disease, or those with serum ALT >2X ULN before initiating treatment. Caution with other potentially hepatotoxic drugs. Monitor ALT levels at least monthly for 6 months after starting therapy, and thereafter every 6-8 weeks. Interrupt therapy if ALT elevation >3X ULN; if likely leflunomide-induced, start cholestyramine washout and monitor liver tests weekly until normalized. If leflunomide-induced liver injury is unlikely, may consider resuming therapy.	1
BBW	arixtra	NA	2004-11-17	2005-05-01	[2010]	NA	http://www.defectivedrug.com/blackbox/arixtra/	Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWHs), heparinoids, or fondaparinux sodium and who are receiving neuraxial anesthesia or undergoing spinal puncture; may result in long-term or permanent paralysis. Increased risk of developing epidural or spinal hematomas in patients using indwelling epidural catheters, concomitant use of other drugs that affect hemostasis (eg, NSAIDs, platelet inhibitors, other anticoagulants), history of traumatic or repeated epidural or spinal puncture, or a history of spinal deformity or spinal surgery. Monitor frequently for signs/symptoms of neurologic impairment; if neurologic compromise noted, urgent treatment is necessary. Consider benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.	1
BBW	arthrotec	NA	1997-12-24	2005-07-01	[2003, 2005, 2006]	NA	http://www.defectivedrug.com/blackbox/arthrotec/	Misoprostol can cause abortion, premature birth or birth defects. Uterine rupture reported when used to induce labor or abortion beyond 8th week of pregnancy. Has an abortifacient property and must not be given to others. Should not be taken by pregnant women. Use only in women of childbearing potential if at high risk for gastric or duodenal ulcers or complications with NSAID therapy; must have had a negative serum pregnancy test within 2 weeks before therapy, must be capable of complying with effective contraceptive measures, and must have received both oral and written warnings of the hazards of misoprostol, risk of contraceptive failure, the danger to other women of childbearing potential should the drug be taken by mistake, and to begin therapy on 2nd or 3rd day of menstrual period. NSAIDs may increase risk of serious cardiovascular (CV) thrombotic events, myocardial infarction (MI), stroke, and serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines. Increased risk of serious GI events in elderly. Contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.	1
BBW	atacand	Candesartan Cilexetil	1998-09-14	2012-04-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009]	pregnancy is detected, discontinue ATACAND as soon as possible	http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm303851.htm	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	atripla	NA	2006-07-20	2008-02-01	[2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm113219.htm	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, reported with the use of nucleoside analogues. Not approved for the treatment of chronic hepatitis B virus (HBV) infection. Severe acute exacerbations of hepatitis B reported in patients coinfected with HBV upon discontinuation of therapy; closely monitor hepatic function for at least several months. If appropriate, initiation of anti-hepatitis B therapy may be warranted.	1
BBW	avalide	NA	1997-09-30	2012-10-31	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://geartsedesdeschmin.jigsy.com/entries/general/irbesartan-vs-irbesartan-plus-hydrochlorothiazide-avalide-black-box-warning-what-is-irbesartan-hydrochlorothiazide-tablets	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus.	1
BBW	avandamet	NA	2003-12-04	2007-11-14	[2004, 2005, 2006, 2007, 2008, 2009]	NA	http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109026.htm	Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive heart failure (CHF) in some patients. After initiation and dose increases, observe for signs and symptoms of heart failure (HF); manage accordingly and consider discontinuation or dose reduction if signs/symptoms develop. Not recommended in patients with symptomatic HF. Contraindicated with established NYHA Class III or IV HF. Lactic acidosis may occur due to metformin accumulation; risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic/renal impairment, and acute CHF. If acidosis is suspected, d/c therapy and hospitalize patient immediately.	1
BBW	avandia	NA	1999-05-28	2007-11-14	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://en.wikipedia.org/wiki/Boxed_warning; http://www.drugwatch.com/actos/black-box-warning.php	Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive heart failure (CHF) in some patients. After initiation and dose increases, observe for signs and symptoms of heart failure (HF); manage accordingly and consider discontinuation or dose reduction if signs/symptoms develop. Not recommended in patients with symptomatic HF. Contraindicated with established NYHA Class III or IV HF.	1
BBW	avapro	NA	1997-09-30	2012-04-20	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://www.bad-drug.net/bad-drug/avapro	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	avastin	NA	2004-02-26	2005-11-03	[2011, 2012, 2013]	NA	http://www.healthboards.com/boards/pain-management/339701-avinza-warning.html	GI perforation reported; d/c with GI perforation. Increased incidence of wound-healing and surgical complications; d/c at least 28 days prior to elective surgery. Do not initiate for at least 28 days after surgery and until surgical wound is fully healed. D/C with wound dehiscence. Severe or fatal hemorrhage, including hemoptysis, GI bleeding, CNS hemorrhage, epistaxis, and vaginal bleeding have occurred; avoid with serious hemorrhage or recent hemoptysis.	1
BBW	avelox	NA	1999-12-10	2008-06-08	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	the FDA ordered a boxed warning on certain antibiotic medications containing fluoroquinolone, which has been linked to tendon ruptures and tendinitis. 	http://en.wikipedia.org/wiki/Boxed_warning	Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages. Risk is further increased in patients >60 yrs of age, patients taking corticosteroids, and with kidney, heart, or lung transplants. May exacerbate muscle weakness with myasthenia gravis; avoid in patients with known history of myasthenia gravis.	1
BBW	avinza	NA	2002-03-20	2005-10-01	[2005, 2006, 2007, 2008, 2009]	NA	http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164410.pdf	Contains pellets of morphine sulfate, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit; assess each patient's risk for opioid abuse or addiction prior to prescribing. Routinely monitor for signs of misuse, abuse, and addiction. Respiratory depression, including fatal cases, may occur even when used as recommended; proper dosing and titration are essential. Monitor for respiratory depression, especially during initiation or following a dose increase. Should only be prescribed by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain. Swallow cap whole or sprinkle contents on applesauce; crushing, chewing, or dissolving the pellets within the cap can cause rapid release and absorption of a potentially fatal dose. Accidental ingestion, especially in children, can result in fatal overdose. Avoid alcohol and alcohol-containing medications while on therapy; may result in an increase of plasma levels and potentially fatal overdose of morphine.	1
BBW	azor	NA	2007-09-26	2013-07-03	[2010]	NA	http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause death/injury to the developing fetus.	1
BBW	benicar	NA	2002-04-25	2012-03-01	[2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258781.htm	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	benicar hct	NA	2003-06-05	2006-01-06	[2005, 2006, 2007, 2008, 2009, 2010]	NA	http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054388.pdf	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	celebrex	NA	1998-10-02	2005-04-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	 increased chances of cardiovascular problems and gastrointestinal bleeding. 	http://en.wikinews.org/wiki/FDA_mandates_%22black_box%22_for_Celebrex,_pulls_Bextra_off_market	May increase risk of serious cardiovascular (CV) thrombotic events, myocardial infarction (MI), and stroke, which can be fatal; increased risk with duration of use and with CV disease (CVD) or risk factors for CVD. Increased risk of serious GI adverse events (eg, bleeding, ulceration, perforation of stomach/intestines) that can be fatal and occur anytime during use without warning symptoms; elderly patients are at a greater risk. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.	1
BBW	celexa	NA	1998-07-17	2011-08-24	[2003, 2004]	NA	http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm	Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Monitor and observe closely for clinical worsening, suicidality, or unusual changes in behavior in patients who are started on antidepressant therapy. Not approved for use in pediatric patients.	1
BBW	cellcept	NA	1995-05-03	2007-10-29	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://www.medpagetoday.com/ProductAlert/Prescriptions/7152	Use during pregnancy is associated with increased risks of 1st trimester pregnancy loss and congenital malformations; counsel females of reproductive potential regarding pregnancy prevention and planning. Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should prescribe mycophenolate mofetil. Manage patients in facilities equipped and staffed with adequate lab and supportive medical resources. Physician responsible for maintenance therapy should have complete information requisite for follow-up of the patient.	1
BBW	chantix	NA	2006-05-10	2009-07-01	[2007, 2008, 2009, 2010]	NA	http://en.wikipedia.org/wiki/Varenicline	Serious neuropsychiatric events including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide reported. Some reported cases may be complicated by nicotine withdrawal symptoms in patients who stopped smoking. Monitor for neuropsychiatric symptoms, including changes in behavior, hostility, agitation, depressed mood, and suicide-related events. Worsening of preexisting psychiatric illness and completed suicide reported in some patients attempting to quit smoking while on therapy. Advise patients and caregivers that the patient should stop taking therapy and contact a healthcare provider immediately if agitation, hostility, depressed mood, changes in behavior or thinking, suicidal ideation, or suicidal behavior occurs. Safety and efficacy not established in patients with serious psychiatric illness (eg, schizophrenia, bipolar disorder, major depressive disorder). Weigh risks against benefits of use.	1
BBW	combivir	NA	1997-09-30	2013-05-17	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://sundchecklighby.jigsy.com/entries/general/fda-approved-combivir-lamivudine-zidovudine-pills-%7C-lamivudine-in-late-pregnancy-to-prevent-perinatal-combivir-pediatric-dose-combivir-hives	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, reported with nucleoside analogues; suspend treatment if lactic acidosis or pronounced hepatotoxicity occurs. Lamivudine: Severe acute exacerbations of hepatitis B reported in patients coinfected with hepatitis B virus (HBV) upon discontinuation of therapy; closely monitor hepatic function for at least several months. If appropriate, initiation of anti-hepatitis B therapy may be warranted. Zidovudine: Associated with hematologic toxicity (eg, neutropenia, anemia), particularly with advanced HIV-1 disease. Symptomatic myopathy associated with prolonged use.	1
BBW	concerta	NA	2000-08-01	2008-06-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011]	NA	http://www.fda.gov/safety/medwatch/safetyinformation/safety-relateddruglabelingchanges/ucm120136.htm	Caution with history of drug dependence or alcoholism. Chronic abusive use may lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes may occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic use may unmask symptoms of underlying disorder that may require follow-up.	1
BBW	cozaar	Losartan	1995-04-14	2014-01-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://en.wikipedia.org/wiki/Losartan	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	cymbalta	NA	2004-08-24	2012-10-01	[2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	http://www.fda.gov/safety/medwatch/safetyinformation/ucm319241.htm	Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor and observe closely for worsening, and for emergence of suicidal thoughts and behavior. Not approved for use in pediatric patients.	1
BBW	depakote	NA	1983-03-10	2013-06-01	[2003, 2004, 2005, 2006, 2007, 2008]	NA	http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm360487.htm	Fatal hepatic failure reported, usually during first 6 months of treatment. Serious/fatal hepatotoxicity may be preceded by nonspecific symptoms (eg, malaise, weakness, lethargy, facial edema, anorexia, vomiting) or loss of seizure control in patients with epilepsy; monitor closely. Monitor LFTs prior to therapy and at frequent intervals thereafter, especially during first 6 months of treatment. Increased risk of developing fatal hepatotoxicity in children <2 yrs of age, especially if on multiple anticonvulsants, with congenital metabolic disorders, with severe seizure disorders with mental retardation, and with organic brain disease; use with extreme caution and as a sole agent. Increased risk of drug-induced acute liver failure and resultant death in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA polymerase gamma (POLG) gene (eg, Alpers-Huttenlocher syndrome). Contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children <2 yrs of age who are clinically suspected of having a mitochondrial disorder. In patients >2 yrs of age who are clinically suspected of having a hereditary mitochondrial disease, drug should only be used after other anticonvulsants have failed; closely monitor for the development of acute liver injury with regular clinical assessments and serum liver testing. May cause major congenital malformations, particularly neural tube defects (eg, spina bifida). May cause decreased IQ scores following in utero exposure. Should only be used to treat pregnant women with epilepsy or bipolar disorder if other medications have failed to control their symptoms or are otherwise unacceptable. Do not administer to a woman of childbearing potential unless the drug is essential to the management of her medical condition; use effective contraception. Life-threatening pancreatitis reported; d/c if pancreatitis is diagnosed and initiate appropriate treatment.	1
BBW	depakote er	NA	2000-08-04	2006-06-12	[2003, 2004, 2005, 2006, 2007, 2008, 2009]	NA	http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/18081s44,18082s27,18723s33,19680s22,20593s15,21168s14lbl.pdf	Fatal hepatic failure may occur, usually during first 6 months of treatment. Serious/fatal hepatotoxicity may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting, or loss of seizure control in patients with epilepsy. Monitor LFTs prior to therapy and at frequent intervals thereafter, especially during first 6 months of treatment. Increased risk of developing fatal hepatotoxicity in children <2 yrs of age, especially if on multiple anticonvulsants, with congenital metabolic disorders, severe seizure disorders with mental retardation, and organic brain disease; use with extreme caution and as a sole agent. Increased risk of drug-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase gamma (POLG) gene (eg, Alpers Huttenlocher Syndrome). Contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children <2 yrs of age who are clinically suspected of having a mitochondrial disorder. In patients >2 yrs of age who are clinically suspected of having a hereditary mitochondrial disease, drug should only be used after other anticonvulsants have failed; closely monitor for the development of acute liver injury with regular clinical assessments and serum liver testing. May cause major congenital malformations, particularly neural tube defects (eg, spina bifida). May cause decreased IQ scores following in utero exposure. Contraindicated in pregnant women treated for prophylaxis of migraine; should only be used to treat pregnant women with epilepsy or bipolar disorder if other medications have failed to control their symptoms or are otherwise unacceptable. Do not administer to a woman of childbearing potential unless the drug is essential to the management of her medical condition; use effective contraception. Life-threatening pancreatitis reported; d/c if pancreatitis is diagnosed and initiate appropriate treatment.	1
BBW	diovan	NA	2001-07-01	2005-08-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	about the risk of extremely low blood pressure hypotension for patients with heart failure	http://webanalytics-lab.com/img/2015/01/19/black-box-warning-on-losartan/; http://www.ehow.com/facts_5511084_diovan-side-effects-reactions.html	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	duragesic	NA	1990-08-07	2008-02-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm113224.htm	Exposes patients and other users to the risk of opioid addiction/abuse/misuse, which may lead to overdose and death; assess risk prior to therapy and monitor all patients regularly for development of these behaviors or conditions. Serious, life-threatening, or fatal respiratory depression may occur; monitor especially during initiation or following a dose increase. Contraindicated for use as a PRN analgesic, in nonopioid tolerant patients, in acute pain, and in postoperative pain. Deaths due to fatal overdose have occurred from accidental exposure; strict adherence to handling/disposal instructions is of utmost importance to prevent accidental exposure. Prolonged use during pregnancy may result in neonatal opioid withdrawal syndrome. Concomitant use with all CYP3A4 inhibitors and discontinuation of a concomitantly administered CYP3A4 inducer may increase plasma concentrations and potentially cause fatal respiratory depression; monitor patients during concomitant therapy. Exposure of application site and surrounding area to direct external heat sources may increase absorption and result in fatal overdose and death; patients who develop fever or increased core body temperature due to strenuous exertion are at increased risk and may require dose adjustment.	1
BBW	elidel	NA	2001-12-02	2005-05-01	[2003, 2004, 2005, 2006]	 a possible cancer risk	http://www.webmd.com/skin-problems-and-treatments/eczema/news/20060119/two-eczema-drugs-get-black-box-warning	Rare cases of malignancy (eg, skin and lymphoma) reported with topical calcineurin inhibitors, including pimecrolimus, although causal relationship is not established. Avoid long-term use, and application should be limited to areas of involvement with atopic dermatitis. Not indicated for children <2 yrs or age.	1
BBW	eloxatin	NA	2006-06-02	2009-03-01	[2011, 2012]	NA	http://www.fda.gov/safety/medwatch/safetyinformation/safety-relateddruglabelingchanges/ucm133529.htm	Anaphylactic reactions reported and may occur within min of administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms of anaphylaxis.	1
BBW	enbrel	NA	2003-01-02	2008-07-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	http://www.fda.gov/safety/medwatch/safetyinformation/safety-relateddruglabelingchanges/ucm121962.htm	Increased risk for developing serious infections (eg, active tuberculosis [TB], latent TB reactivation, invasive fungal infections, bacterial/viral infections, opportunistic infections) leading to hospitalization or death, mostly with concomitant use with immunosuppressants (eg, methotrexate [MTX], corticosteroids). D/C if serious infection or sepsis develops. Active/latent reactivation of TB may present with disseminated or extrapulmonary disease; test for latent TB before and during therapy and initiate treatment for latent TB prior to therapy. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Monitor for development of infection during and after treatment, including development of TB in patients who tested negative for latent TB infection prior to therapy. Lymphoma and other malignancies, some fatal, reported in children and adolescents.	1
BBW	epivir	NA	1995-11-21	2008-02-01	[2003, 2004, 2005]	NA	http://www.fda.gov/safety/medwatch/safetyinformation/safety-relateddruglabelingchanges/ucm113219.htm	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, reported with nucleoside analogues; suspend treatment if lactic acidosis or pronounced hepatotoxicity occurs. Severe acute exacerbations of hepatitis B reported in patients coinfected with hepatitis B virus (HBV) upon discontinuation of therapy; closely monitor hepatic function for at least several months. If appropriate, initiation of anti-hepatitis B therapy may be warranted. Epivir tabs and sol, used to treat HIV-1 infection, contain higher dose of lamivudine than Epivir-HBV tabs and sol, used to treat chronic HBV infection; only use appropriate dosing forms for HIV-1 treatment.	1
BBW	epogen	NA	1989-06-30	2009-03-09	[2003, 2011, 2012, 2013]	NA	http://www.medpagetoday.com/ProductAlert/Prescriptions/5231	Increased risk of death, myocardial infarction (MI), stroke, venous thromboembolism (VTE), thrombosis of vascular access, and tumor progression or recurrence. Use the lowest dose sufficient to reduce/avoid the need for RBC transfusions. Chronic Kidney Disease (CKD): Greater risks for death, serious adverse cardiovascular (CV) reactions, and stroke when administered to target Hgb level >11g/dL. Cancer: Shortened overall survival and/or increased risk of tumor progression or recurrence in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. Must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense drug to patients. Use only for anemia from myelosuppressive chemotherapy. Not indicated for patients receiving myelosuppressive chemotherapy when anticipated outcome is cure. D/C following completion of a chemotherapy course. Perisurgery: Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended.	1
BBW	epzicom	NA	2006-05-22	2009-03-01	[2006, 2007, 2008, 2009, 2010]	NA	http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm133471.htm	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, reported with nucleoside analogues. Abacavir: Serious and sometimes fatal hypersensitivity reactions (multiorgan clinical syndrome) reported; d/c as soon as suspected and never restart therapy with any abacavir-containing product. Patients with HLA-B*5701 allele are at high risk for hypersensitivity; screen for HLA-B*5701 allele prior to therapy. Lamivudine: Severe acute exacerbations of hepatitis B reported in patients coinfected with hepatitis B virus (HBV) upon discontinuation of therapy; closely monitor hepatic function for at least several months. If appropriate, initiation of anti-hepatitis B therapy may be warranted.	1
BBW	erbitux	NA	2004-02-12	2006-03-01	[2011]	NA	http://www.defectivedrug.com/blackbox/erbitux/	Serious infusion reactions, some fatal, reported; immediately interrupt and permanently d/c infusion if these reactions occur. Cardiopulmonary arrest and/or sudden death occurred in patients with squamous cell carcinoma of the head and neck (SCCHN) treated with cetuximab in combination with radiation therapy or with European Union (EU)-approved cetuximab in combination with platinum-based therapy with 5-fluorouracil (5-FU); closely monitor serum electrolytes during and after therapy.	1
BBW	exforge	NA	2007-06-20	2008-07-01	[2009, 2010]	NA	http://www.fda.gov/safety/medwatch/safetyinformation/safety-relateddruglabelingchanges/ucm121835.htm	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury/death to the developing fetus.	1
BBW	fentora	NA	2006-09-25	2008-02-01	[2007, 2008, 2009, 2010]	NA	http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm113227.htm	Fatal respiratory depression may occur. Contraindicated in the management of acute or postoperative pain (eg, headache/migraine) and in opioid-nontolerant patients. Keep out of reach of children. Concomitant use with CYP3A4 inhibitors may increase plasma levels, and may cause fatal respiratory depression. Do not convert patients on a mcg-per-mcg basis from any other fentanyl products to Fentora. Do not substitute for any other fentanyl products; may result in fatal overdose. Contains fentanyl with abuse liability similar to other opioid analgesics. Available only through a restricted program called TIRF REMS Access program (Transmucosal Immediate Release Fentanyl Risk Evaluation Mitigation Strategy) due to risk of misuse, abuse, addiction, and overdose. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program.	1
BBW	geodon	NA	2001-02-05	2008-06-16	[2011]	 increased risk of mortality in elderly patients treated for dementia-related psychosis. 	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm	Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; most deaths appeared to be cardiovascular (CV) (eg, heart failure [HF], sudden death) or infectious (eg, pneumonia) in nature. Not approved for treatment of dementia-related psychosis.	1
BBW	geodon oral	ziprasidone	2001-02-05	2005-04-11	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152299.htm	Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; most deaths appeared to be cardiovascular (CV) (eg, heart failure [HF], sudden death) or infectious (eg, pneumonia) in nature. Not approved for treatment of dementia-related psychosis.	1
BBW	herceptin	NA	1998-09-25	2006-11-01	[2011, 2012, 2013]	NA	http://www.defectivedrug.com/blackbox/herceptin/	May result in cardiac failure; incidence and severity were highest with anthracycline-containing chemotherapy regimens. Evaluate left ventricular function prior to and during treatment; d/c in patients receiving adjuvant therapy and withhold in patients with metastatic disease for clinically significant decrease in left ventricular function. May result in serious and fatal infusion reactions and pulmonary toxicity; interrupt infusion for dyspnea or clinically significant hypotension, and monitor until symptoms completely resolve. D/C for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Exposure during pregnancy may result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.	1
BBW	humira	NA	2002-12-30	2009-11-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member.	http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm194134.htm	Increased risk of serious infections (eg, active tuberculosis [TB] including latent TB reactivation, invasive fungal, bacterial, viral, and other infections due to opportunistic pathogens) leading to hospitalization or death, mostly with concomitant use of immunosuppressants (eg, methotrexate [MTX], corticosteroids). D/C if serious infection or sepsis develops. Active/latent reactivation TB patients have frequently presented with disseminated or extrapulmonary disease; test for latent TB before and during therapy and initiate treatment for latent TB prior to adalimumab use. Invasive fungal infections reported; consider empiric antifungal therapy in patients at risk who develop severe systemic illness. Monitor patients closely for development of infection during and after treatment, including development of TB in patients who tested negative for latent TB infection prior to therapy. Lymphoma and other malignancies, some fatal, reported in children and adolescents. Postmarketing cases of aggressive and fatal hepatosplenic T-cell lymphoma (HSTCL) reported in patients with Crohn's disease (CD) or ulcerative colitis (UC) and the majority were in adolescent and young adult males; all of these patients were treated concomitantly with azathioprine or 6-mercaptopurine.	1
BBW	invega	NA	2006-12-19	2008-06-16	[2008, 2009, 2010]	 increased risk of mortality in elderly patients treated for dementia-related psychosis. 	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm	Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; most deaths appeared to be cardiovascular (CV) (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Not approved for the treatment of patients with dementia-related psychosis.	1
BBW	levaquin	NA	1996-12-20	2008-07-08	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011]	 FDA ordered a boxed warning on certain antibiotic medications containing fluoroquinolone, which has been linked to tendon ruptures and tendinitis.	http://en.wikipedia.org/wiki/Boxed_warning	Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages. Risk is further increased with patients >60 yrs of age, patients taking corticosteroids, and with kidney, heart, or lung transplants. May exacerbate muscle weakness with myasthenia gravis; avoid in patients with known history of myasthenia gravis.	1
BBW	lotensin	NA	1991-06-25	2012-03-01	[2003]	NA	http://newyork.legalexaminer.com/fda-prescription-drugs/physicians-alert-the-public-to-potentially-lifethreatening-ace-inhibitor-side-effects/	D/C when pregnancy is detected. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus.	1
BBW	lovenox	NA	1993-03-29	2013-10-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011]	Increased Risk of Hemorrhage	http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm180210.htm	Epidural or spinal hematomas resulting in long-term or permanent paralysis may occur in patients anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. Increased risk with indwelling epidural catheters, concomitant use of other drugs that affect hemostasis (eg, NSAIDs, platelet inhibitors, other anticoagulants), history of traumatic or repeated epidural or spinal punctures, a history of spinal deformity or spinal surgery, or when optimal timing between the administration of enoxaparin and neuraxial procedures is not known. Monitor frequently for signs/symptoms of neurological impairment; if neurological compromise noted, urgent treatment is necessary. Consider benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.	1
BBW	mobic	NA	2000-06-01	2005-08-01	[2003, 2004, 2005, 2006]	NA	http://www.defectivedrug.com/blackbox/mobic/	NSAIDs may cause an increased risk of serious CV thrombotic events, myocardial infarction, stroke, and serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. Elderly patients at greater risk for serious GI events. Contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.	1
BBW	nuvaring	NA	2001-10-03	2008-04-01	[2006, 2007, 2008, 2009, 2010]	NA	http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm117851.htm	Cigarette smoking increases the risk of serious cardiovascular (CV) events. Risk increases with age and with number of cigarettes smoked. Not for use by women >35 yrs of age and smoke.	1
BBW	paxil	NA	1996-07-10	2005-01-01	[2003, 2004]	NA	http://www.defectivedrug.com/blackbox/paxil/	Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Monitor and observe closely for clinical worsening, suicidality, or unusual changes in behavior in patients who are started on antidepressant therapy. Not approved for use in pediatric patients.	1
BBW	plavix	NA	1999-02-26	2010-03-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012]	NA	http://en.wikipedia.org/wiki/Clopidogrel	Effectiveness is dependent on activation to an active metabolite via CYP2C19. Poor metabolizers of CYP2C19 with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention treated with clopidogrel at recommended doses exhibit higher cardiovascular (CV) event rates than patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.	1
BBW	procrit	NA	1989-06-01	2007-03-09	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013]	NA	http://www.medpagetoday.com/ProductAlert/Prescriptions/5231	Increased risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence. Use the lowest dose sufficient to reduce/avoid the need for RBC transfusions. Chronic kidney disease (CKD): Greater risks for death, serious adverse cardiovascular (CV) reactions, and stroke when administered to target Hgb level >11g/dL. Cancer: Shortened overall survival and/or increased risk of tumor progression or recurrence in patients with breast, non-small-cell lung, head and neck, lymphoid, and cervical cancers. Must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense drug to patients. Use only for anemia from myelosuppressive chemotherapy. Not indicated for patients receiving myelosuppressive chemotherapy when anticipated outcome is cure. D/C following completion of chemotherapy course. Perisurgery: Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended.	1
BBW	prograf	NA	1994-04-08	2005-05-10	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	a possible cancer risk	http://www.webmd.com/skin-problems-and-treatments/eczema/news/20060119/two-eczema-drugs-get-black-box-warning	Immunosuppression may lead to increased risk of lymphoma and other malignancies, particularly of the skin. Increased susceptibility to infections (bacterial, viral, fungal, protozoal, opportunistic). Should only be prescribed by physicians experienced in immunosuppressive therapy and management of organ transplant patients.	1
BBW	prozac	NA	1987-12-29	2005-02-01	[2003, 2004, 2005]	NA	http://www.defectivedrug.com/blackbox/prozac/	Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for worsening and for emergence of suicidal thoughts and behaviors in patients who are started on antidepressant therapy. Not approved for use in children <7 yrs of age.	1
BBW	remicade	NA	1998-08-24	2001-10-23	[2011, 2012, 2013]	NA	http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm172751.htm	Increased risk for developing serious infections (eg, active tuberculosis [TB], latent TB reactivation, invasive fungal infections, bacterial/viral infections, opportunistic infections) leading to hospitalization or death, mostly with concomitant use with immunosuppressants (eg, methotrexate [MTX], corticosteroids). D/C if serious infection or sepsis develops. Active/latent reactivation TB may present with disseminated or extrapulmonary disease; test for latent TB before and during therapy and initiate treatment for latent TB prior to infliximab use. Invasive fungal infections reported; consider empiric antifungal therapy in patients at risk who develop severe systemic illness. Consider risks and benefits prior to therapy in patients with chronic or recurrent infection. Monitor patients for development of infection during and after treatment, including development of TB in patients who tested negative for latent TB infection prior to therapy. Lymphoma and other malignancies, some fatal, reported in children and adolescents. Postmarketing cases of aggressive and fatal hepatosplenic T-cell lymphoma (HSTCL) reported in patients with Crohn's disease (CD) or ulcerative colitis (UC) and the majority were in adolescent and young adult males; all of these patients were treated concomitantly with azathioprine or 6-mercaptopurine.	1
BBW	revlimid	NA	2005-12-27	2006-06-01	[2008, 2009]	NA	http://www.defectivedrug.com/blackbox/revlimid/	Do not use during pregnancy; may cause birth defects or embryo-fetal death. Females of reproductive potential should have 2 negative pregnancy tests prior to treatment and must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after treatment. Available only through a restricted distribution program, the Revlimid REMS program. May cause significant neutropenia and thrombocytopenia. Patients on therapy for del 5q myelodysplastic syndromes (MDS) should have their CBC monitored weekly for the first 8 weeks of therapy and at least monthly thereafter; may require dose interruption and/or reduction and use of blood product support and/or growth factors. Increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) reported in patients with multiple myeloma treated with lenalidomide and dexamethasone; observe for signs/symptoms of thromboembolism. Instruct patients to seek medical care if symptoms such as SOB, chest pain, or arm or leg swelling develop. Consider taking prophylactic measures for venous thromboembolism based on assessment of individual's underlying risk factors.	1
BBW	risperdal	risperidone	1993-12-29	2008-06-16	[2003, 2004, 2005, 2006, 2007, 2008]	 increased risk of mortality in elderly patients treated for dementia-related psychosis. 	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm	Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Not approved for the treatment of patients with dementia-related psychosis.	1
BBW	rituxan	NA	1997-11-26	2013-09-25	[2011, 2012, 2013]	FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)	http://www.fda.gov/drugs/drugsafety/ucm366406.htm	Serious, including fatal infusion reactions reported; deaths within 24 hrs of infusion have occurred. Monitor patients closely. D/C for severe reaction and treat for Grade 3/4 reactions. Severe, including fatal, mucocutaneous reactions may occur. Hepatitis B virus (HBV) reactivation can occur, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation; monitor patients during and after treatment. D/C therapy and concomitant medications in the event of HBV reactivation. Fatal progressive multifocal leukoencephalopathy (PML) may occur.	1
BBW	seroquel	quetiapine	1997-10-01	2008-06-16	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012]	 increased risk of mortality in elderly patients treated for dementia-related psychosis. 	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm	Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Not approved for the treatment of patients with dementia-related psychosis. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for worsening, and for emergence of suicidal thoughts and behaviors in patients who are started on antidepressant therapy. Not approved for use in pediatric patients <10 yrs of age.	1
BBW	sporanox	Itraconazole	1992-09-11	2012-04-01	[2003]	Cardiac Effects and Drug Interactions:Ä	http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm303524.htm	Contraindicated with cisapride, oral midazolam, nisoldipine, felodipine, pimozide, quinidine, dofetilide, triazolam, levacetylmethadol (levomethadyl), lovastatin, simvastatin, ergot alkaloids (eg, dihydroergotamine, ergometrine [ergonovine], ergotamine, methylergometrine [methylergonovine]), or methadone. May increase plasma concentrations of drugs metabolized by potent CYP3A4 inhibitor pathway. Serious cardiovascular events (eg, QT prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest, and/or sudden death) reported with cisapride, pimozide, methadone, levacetylmethadol, or quinidine. Reassess or d/c use if signs/symptoms of congestive heart failure (CHF) occur. (Cap) Do not use cap for onychomycosis with ventricular dysfunction (eg, CHF or history of CHF).	1
BBW	strattera	NA	2003-01-10	2008-05-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://www.fda.gov/safety/medwatch/safetyinformation/safety-relateddruglabelingchanges/ucm119297.htm	Increased risk of suicidal ideation in short-term studies in children or adolescents with attention-deficit hyperactivity disorder (ADHD); balance this risk with the clinical need. Closely monitor for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Not approved for major depressive disorder.	1
BBW	synthroid	NA	2002-02-24	2008-07-01	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2012, 2013]	NA	NA	Do not use for the treatment of obesity or weight loss; doses within range of daily hormonal requirements are ineffective for weight reduction in euthyroid patients. Serious or life-threatening manifestations of toxicity may occur when given in larger doses, particularly when given in association with sympathomimetic amines.	1
BBW	testim	NA	2002-10-31	2009-09-01	[2010]	NA	NA	Virilization reported in children secondarily exposed to testosterone gel. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel. Advise patients to strictly adhere to recommended instructions for use.	1
BBW	thalomid	NA	2003-06-20	2006-05-01	[2003, 2004, 2005, 2006, 2007, 2008]	NA	http://www.defectivedrug.com/blackbox/thalomid/	Severe birth defects or embryo-fetal death may occur if taken during pregnancy. Should never be used by pregnant women or females who could become pregnant. Approved for marketing only under a special restricted distribution program called the "THALOMID REMS program." May increase risk of venous thromboembolism in patients with multiple myeloma, especially with standard chemotherapeutic agents including dexamethasone; observe for signs/symptoms of thromboembolism. Instruct patients to seek medical care if symptoms such as SOB, chest pain, or arm or leg swelling develop. Consider thromboprophylaxis based on assessment of individual's underlying risk factors.	1
BBW	viramune	NA	2001-08-01	2005-02-01	[2003, 2004]	NA	http://www.defectivedrug.com/blackbox/viramune/	Severe, life-threatening, and in some cases fatal, hepatotoxicity (particularly in the first 18 weeks) and skin reactions (eg, Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], hypersensitivity reactions) reported. Increased risk of hepatotoxicity reported in women and patients with higher CD4	1
BBW	viread	NA	2001-10-26	2008-05-16	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://google2.fda.gov/search?q=viread&client=FDAgov&proxystylesheet=FDAgov&output=xml_no_dtd&site=FDAgov-MedWatch-Safety&requiredfields=-archive:Yes&sort=date:D:L:d1&filter=0&ie=UTF-8&ulang=en&access=p&entqr=3&entqrm=0&wc=200&wc_mc=1&oe=UTF-8&ud=1&&start=0	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, reported with the use of nucleoside analogues in combination with other antiretrovirals. Severe acute exacerbations of hepatitis reported in hepatitis B virus (HBV)-infected patients who have discontinued therapy; closely monitor hepatic function with both clinical and lab follow-up for at least several months. If appropriate, resumption of anti-hepatitis B therapy may be warranted.	1
BBW	vyvanse	NA	2007-02-23	2008-11-01	[2008, 2009, 2010, 2011, 2012, 2013]	NA	http://www.fda.gov/safety/medwatch/safetyinformation/safety-relateddruglabelingchanges/ucm121381.htm	CNS stimulants (amphetamines and methylphenidate-containing products) have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.	1
BBW	wellbutrin xl	NA	2003-10-08	2006-02-01	[2004, 2005, 2006, 2007, 2008, 2009, 2010]	NA	http://www.defectivedrug.com/blackbox/wellbutrin/	Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Monitor and observe closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients. Not approved for smoking cessation; neuropsychiatric reactions reported in patients taking bupropion for smoking cessation.	1
BBW	xarelto	NA	2011-07-01	2014-03-01	[2013]	To reduce the potential risk of bleeding	http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm367392.htm	Premature discontinuation increases the risk of thrombotic events. If therapy is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. Epidural or spinal hematomas have occurred in patients treated with rivaroxaban who are receiving neuraxial anesthesia or undergoing spinal puncture; long-term or permanent paralysis may result. Increased risk of developing epidural or spinal hematomas in patients using indwelling epidural catheters, concomitant use of other drugs that affect hemostasis (eg, NSAIDs, platelet inhibitors, other anticoagulants), history of traumatic or repeated epidural or spinal puncture, history of spinal deformity or spinal surgery, and when optimal timing between the administration of therapy and neuraxial procedure is not known. Monitor frequently for signs/symptoms of neurological impairment; urgent treatment is necessary if neurological compromise occurs. Consider benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.	1
BBW	xolair	NA	2003-06-20	2007-07-03	[2013]	NA	http://www.webmd.com/asthma/news/20070703/xolair-gets-black-box-warning	Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of throat or tongue reported as early as after the 1st dose and beyond 1 yr of therapy; closely observe patients. Inform of the signs/symptoms of anaphylaxis and instruct to seek immediate medical care should symptoms occur.	1
BBW	yasmin 28	NA	2001-05-11	2008-12-01	[2003, 2004, 2005, 2006, 2007, 2008]	In December 2008, an FDA panel voted in favor of strengthening warnings on YAZ birth control pill labels. The FDAês most serious label, the black-box warning, appears on all Yaz and Yasmin packaging. It cautions women who smoke about an increased risk of serious cardiovascular side effects that may occur if they use either drug.	http://www.drugwatch.com/yaz/lawsuit.php; http://www.lawyersandsettlements.com/lawsuit/yasmin-side-effects-yaz-blood.html#.VOZBL0vWqL4	Cigarette smoking increases the risk of serious cardiovascular (CV) side effects from combination oral contraceptive (COC) use. Risk increases with age (>35 yrs of age) and with the number of cigarettes smoked. Should not be used by women who are >35 yrs of age and smoke.	1
BBW	yaz	NA	2006-03-16	2008-12-01	[2007, 2008, 2009, 2010]	In December 2008, an FDA panel voted in favor of strengthening warnings on YAZ birth control pill labels. The FDAês most serious label, the black-box warning, appears on all Yaz and Yasmin packaging. It cautions women who smoke about an increased risk of serious cardiovascular side effects that may occur if they use either drug.	http://www.drugwatch.com/yaz/lawsuit.php; http://www.lawyersandsettlements.com/lawsuit/yasmin-side-effects-yaz-blood.html#.VOZBL0vWqL4	Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. Risk increases with age (>35 yrs of age) and with the number of cigarettes smoked. Should not be used by women who are >35 yrs of age and smoke.	1
BBW	zerit	NA	1994-06-24	2009-02-01	[2003, 2004]	NA	http://google2.fda.gov/search?q=zerit&client=FDAgov&proxystylesheet=FDAgov&output=xml_no_dtd&site=FDAgov-MedWatch-Safety&requiredfields=-archive:Yes&sort=date:D:L:d1&filter=0&ie=UTF-8&ulang=en&&access=p&entqr=3&entqrm=0&wc=200&wc_mc=1&oe=UTF-8&ud=1&start=10	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, reported with nucleoside analogues. Fatal lactic acidosis reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents; use with caution. Fatal and nonfatal pancreatitis reported when used as part of a combination regimen that included didanosine.	1
BBW	zoloft	NA	1992-02-11	2005-02-01	[2003, 2004, 2005, 2006, 2007]	NA	http://www.defectivedrug.com/blackbox/zoloft/	Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Monitor and observe closely for clinical worsening, suicidality, or unusual changes in behavior in patients who are started on antidepressant therapy. Not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD).	1
BBW	zyprexa	NA	1996-10-01	2008-06-16	[2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011]	 increased risk of mortality in elderly patients treated for dementia-related psychosis. 	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm	Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; most deaths appeared to be cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Not approved for the treatment of patients with dementia-related psychosis. When used with fluoxetine, refer to the Boxed Warning section of the PI for Symbyax.	1
